Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens
- PMID: 11961234
- DOI: 10.1046/j.1537-2995.2002.00051.x
Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens
Abstract
Background: HLA-C antigens have been thought to be of little significance in determining the efficacy of platelet transfusions. However, six alloimmunized patients were encountered who were refractory to platelet transfusions because of anti-HLA-Cw3, -Cw3, -Cw7, or -Cw8.
Study design and methods: Between 1995 and the present, 88 patients with hematologic malignancies became refractory to random-donor platelet transfusions due to HLA antibodies. HLA-A- and HLA-B-compatible platelet transfusions were successful in boosting platelet levels with 82 of the patients. This study concerns the remaining six HLA-immunized patients who were refractory to HLA-A- and HLA-B-compatible platelet transfusions. The response to the platelet transfusions was assessed by calculating both 1- and 24-hour posttransfusion CCIs for each transfusion.
Results: The average CCI(1 hour) and CCI(24 hours) in all patients were 20.0 and 12.8 for HLA-A-, HLA-B-, and HLA-C-compatible transfusions and were 1.4 and 1.2 for HLA-A- and HLA-B-compatible but HLA-C-incompatible transfusions, respectively (p < 0.001).
Conclusion: These findings clearly indicate that matching of the HLA-C antigens is also required in some alloimmunized patients to obtain the effectiveness of platelet transfusions.
Similar articles
-
A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.Br J Haematol. 1996 Mar;92(4):1005-10. doi: 10.1046/j.1365-2141.1996.414953.x. Br J Haematol. 1996. PMID: 8616059
-
Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.Transfusion. 1995 Aug;35(8):645-52. doi: 10.1046/j.1537-2995.1995.35895357895.x. Transfusion. 1995. PMID: 7631404
-
An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.Blood. 1987 Jul;70(1):23-30. Blood. 1987. PMID: 3474041
-
Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.Haematologia (Budap). 1998;29(1):1-11. Haematologia (Budap). 1998. PMID: 9704252 Review.
-
Management of the Platelet Refractory Patient.Hematol Oncol Clin North Am. 2016 Jun;30(3):665-77. doi: 10.1016/j.hoc.2016.01.008. Epub 2016 Apr 5. Hematol Oncol Clin North Am. 2016. PMID: 27113003 Review.
Cited by
-
Simultaneous genotyping for human platelet antigen systems and HLA-A and HLA-B loci by targeted next-generation sequencing.Front Immunol. 2022 Sep 29;13:945994. doi: 10.3389/fimmu.2022.945994. eCollection 2022. Front Immunol. 2022. PMID: 36263028 Free PMC article.
-
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia.Front Immunol. 2022 Sep 20;13:1018047. doi: 10.3389/fimmu.2022.1018047. eCollection 2022. Front Immunol. 2022. PMID: 36203567 Free PMC article.
-
Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis.Front Med (Lausanne). 2022 May 6;9:873500. doi: 10.3389/fmed.2022.873500. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35602482 Free PMC article.
-
Toward in Vitro Production of Platelet from Induced Pluripotent Stem Cells.Stem Cell Rev Rep. 2022 Oct;18(7):2376-2387. doi: 10.1007/s12015-022-10366-4. Epub 2022 Apr 9. Stem Cell Rev Rep. 2022. PMID: 35397051 Review.
-
Generation of HLA Universal Megakaryocytes and Platelets by Genetic Engineering.Front Immunol. 2021 Oct 27;12:768458. doi: 10.3389/fimmu.2021.768458. eCollection 2021. Front Immunol. 2021. PMID: 34777386 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
